Skip to main content

Featured

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD
Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD
The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.  ...

From the Editor's Desk

A Letter to Oncology Data Advisor Readers From Rahul Banerjee, MD, FACP, and Thomas Abrams, MD
A Letter to Oncology Data Advisor Readers From Rahul Banerjee, MD, FACP, and Thomas Abrams, MD
Oncology Data Advisor is excited to announce that Rahul Banerjee, MD, FACP, has been appointed the new Editor in Chief. Dr. Banerjee, an Assistant Professor of Medicine in the Division of Oncology at the University of Washington, Fred Hutchinson Cancer Center, has taken over the role from Thomas Abrams, MD, Assistant Professor of Medicine at Harvard Medical School, who has served in the role since 2021. They are both excited about the transition and have written brief outro and intro letter...

Expert Analysis

Practice Patterns

Noteworthy Headlines

Most Popular

    Podcast Spotlight